You are here

Assay and Instrument Development for Diagnosis of Prion Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI069616-01A1
Agency Tracking Number: AI069616
Amount: $600,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Timeline
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
CREATV MICROTECH, INC. 11609 LAKE POTOMAC DR
POTOMAC, MD 20854
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: Yes
Principal Investigator
 PEIZUAN ZHU
 () -
Business Contact
 PETE AMSTUTZ
Phone: (301) 983-1650
Email: pete@creatvmicrotech.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Prion diseases are a family of fatal neurodegenerative diseases that are caused by infectious misfolded prion proteins (PrPSc) in both animals and humans. Prion diseases can occur spontaneously and can be contracted by multiple routes: consumption of contaminated foods, blood transfusion, organ and tissue transplant, and contamination of medical devices. Prion diseases have a years-, and even decades-long incubation period before onset of symptom. PrPSc are extraordinarily resistant to classic medical decontamination procedures. These factors raise major concerns about potential transmission of the diseases and the need for tools for timely diagnosis. Currently the diseases are diagnosed antemortem imperfectly based on clinical signs of neural disorders, and confirmed only postmortem by neuropathological and immunohistochemical analysis of brain tissue. A sensitive blood screening test is urgently needed for protecting against the risk of disease transmission. This Small Business Innovation Research proposes to apply a novel assay, coupled with sensitive biosensor technology, to develop a living test of prion disease. The assay will be able to quantify normal and variant prions. The initial goal for sensitivity in Phase I is 5 pg/ml in blood with further improvement to be made in Phase II.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government